- Personal FinanceCompare Online BrokersTop StocksAlternative Investing
- CryptoGet StartedNFTs
Adaptimmune Therapeutics (NASDAQ:ADAP), Quotes and News Summary
Adaptimmune Therapeutics (NASDAQ: ADAP)
Earnings
see more| Q2 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-08-08 | ||||||
| REV | |||||||
| Q1 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.220 | -0.050 | 0.1700 | ||||
| REV | 3.290M | 3.575M | 285.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Adaptimmune Therapeutics Questions & Answers
You can purchase shares of Adaptimmune Therapeutics (NASDAQ: ADAP) through any online brokerage.
Other companies in Adaptimmune Therapeutics’s space includes: Outlook Therapeutics (NASDAQ:OTLK), Voyager Therapeutics (NASDAQ:VYGR), Burning Rock Biotech (NASDAQ:BNR), LianBio (NASDAQ:LIAN) and PepGen (NASDAQ:PEPG).
The latest price target for Adaptimmune Therapeutics (NASDAQ: ADAP) was reported by SVB Leerink on Monday, May 9, 2022. The analyst firm set a price target for 3.00 expecting ADAP to rise to within 12 months (a possible 73.41% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Adaptimmune Therapeutics (NASDAQ: ADAP) is $1.73 last updated July 6, 2022, 8:00 PM UTC.
There are no upcoming dividends for Adaptimmune Therapeutics.
Adaptimmune Therapeutics’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Adaptimmune Therapeutics.
Adaptimmune Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.